TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today reported positive clinical results from multiple studies with TRC105 and TRC102 at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
We are going to take a deep look at TRACON Pharmaceuticals Inc. (NASDAQ:TCON) to get a better view of the company and its prevailing status, as well as the prospect it may offer for investors. Today’s prime focus will be a fundamental assessment of the equity from top to bottom.
As such, let’s begin with the top line, i.e. revenue trends. Last quarter, the firm saw its overall revenue came at $626,000. That represents a change in revenues, on a quarterly/yearly basis, of 1%. If it is translated that into sequential terms, the firm witnessed sales grow by 0.01% from quarter to quarter.
It?s important to track the top line data. There’s no better way to compute the end market?s reception of a firm?s products. But no one wins without bottom line performance, which is what is required to look at next.
TRACON Pharmaceuticals Inc. (NASDAQ: TCON) is intriguing when segregated to its core data. For shareholders, provided the total diluted due shares of 16.21M, this means earnings per share of $(0.44). Note, this assesses with a consensus analyst projection of $-0.52 in EPS for its next quarterly report.
Given that data, now is the time to turn to a thorough glance across analyst projections for the firm going forward.
At present, analysts have a consensus average recommendation of Buy. This is grounded on a total of 5. While we don’t recommend taking analyst calls as face value strategies for action in a portfolio, we do consider it is vital to note where consensus is on an equity to understand what basic assumptions are possibly already discounted into pricing of shares.
As far as price targets, market analysts have an average target of $10.10. In addition, for next year, estimates of a fiscal year forecast is -1.37 in total EPS. On a median price to earnings ratio, that outlook results in a valuation of $9,999 times earnings.
For TRACON Pharmaceuticals Inc. (NASDAQ:TCON), the firm presently holds around $32.22M in cash. That cash is balanced against around $343,000 in total current liabilities.
The firm’s debt is $falling, while total assets are $37.92M balanced by total liablities of $14.93M. The free cash flow last quarter was $(7.57M), representing a net change in cash of $(3.49M). On a net operating level, the cash flow was about $(7.57M).
Let’s take a look at the technical analysis.
The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is approaching oversold territory. Be watchful of a trend reversal.
We will apprise the interesting story of TRACON Pharmaceuticals Inc. (NASDAQ:TCON) as new events transpire.